NEW YORK, Nov. 17, 2016 /PRNewswire/ --
The market value for intrathecal pump will undergo steady growth over the projected period driven by greater patient awareness and technological advancement. Single digit growth in units sold will occur as patient awareness of the benefits of these devices is increasing. There is a high level of patient satisfaction with these devices which leads to high replacement rates and the lower satisfaction rates with neurostimulators drives growth in pumps as well. The market for intrathecal pumps is impacted by trends in the neurostimulation market. Due to the higher reimbursement for neurostimulation, the market for intrathecal pumps did not witness significant growth prior to 2014 when the reimbursement for neurostimulation trials was reduced. As a result of this change, the market saw an increase in growth after these changes. However, competing neurostimulation is still eroding some of the pain pump market since neurostimulation tends to be the initial line of treatment for chronic back pain.
An intrathecal pump is an implantable medical device that delivers medication to the intrathecal space surrounding the spinal cord. The drug pump reduces the reliance of patients on oral or intravenous medications and can minimize the associated side effects while controlling their symptoms. Lower doses of medications are generally required since the drug delivery is more targeted. Before a pump is implanted into the patient, the therapeutic effect of the intrathecal opioid therapy is tested with an external pump; the pump is not implanted if there are no clear and satisfactory effects in the trial application.
St. Jude Medical
Codman & Shurtleff
Read the full report: http://www.reportlinker.com/p04353040-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]
Intl: +1 339-368-6001